Yanning Xu, Arash Derakhshan, Ola Hysaj, Lea Wildisen, Till Ittermann, Alessandro Pingitore, Nazanin Abolhassani, Marco Medici, Lambertus A L M Kiemeney, Niels P Riksen, Robin P F Dullaart, Stella Trompet, Marcus Dörr, Suzanne J Brown, Börge Schmidt, Dagmar Führer-Sakel, Mark P J Vanderpump, Axel Muendlein, Heinz Drexel, Howard A Fink, M Kamran Ikram, Maryam Kavousi, Connie M Rhee, Isabela M Bensenor, Fereidoun Azizi, Graeme J Hankey, Massimo Iacoviello, Misa Imaizumi, Graziano Ceresini, Luigi Ferrucci, José A Sgarbi, Douglas C Bauer, Nick Wareham, Kristien Boelaert, Stephan J L Bakker, J Wouter Jukema, Bert Vaes, Giorgio Iervasi, Bu B Yeap, Rudi G J Westendorp, Tim I M Korevaar, Henry Völzke, Salman Razvi, Jacobijn Gussekloo, John P Walsh, Anne R Cappola, Nicolas Rodondi, Robin P Peeters, Layal Chaker
BACKGROUND: Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4 ) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease and mortality. METHODS: This systematic review and individual participant data (IPD) meta-analysis identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a systematic search via Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from Jan 1, 2011, to Feb 12, 2017 with an updated search to Oct 13, 2022 (cohorts found in the second search were not included in the IPD)...
September 8, 2023: Lancet Diabetes & Endocrinology